Literature DB >> 16079851

Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis.

Zhenbang Chen1, Lloyd C Trotman, David Shaffer, Hui-Kuan Lin, Zohar A Dotan, Masaru Niki, Jason A Koutcher, Howard I Scher, Thomas Ludwig, William Gerald, Carlos Cordon-Cardo, Pier Paolo Pandolfi.   

Abstract

Cellular senescence has been theorized to oppose neoplastic transformation triggered by activation of oncogenic pathways in vitro, but the relevance of senescence in vivo has not been established. The PTEN and p53 tumour suppressors are among the most commonly inactivated or mutated genes in human cancer including prostate cancer. Although they are functionally distinct, reciprocal cooperation has been proposed, as PTEN is thought to regulate p53 stability, and p53 to enhance PTEN transcription. Here we show that conditional inactivation of Trp53 in the mouse prostate fails to produce a tumour phenotype, whereas complete Pten inactivation in the prostate triggers non-lethal invasive prostate cancer after long latency. Strikingly, combined inactivation of Pten and Trp53 elicits invasive prostate cancer as early as 2 weeks after puberty and is invariably lethal by 7 months of age. Importantly, acute Pten inactivation induces growth arrest through the p53-dependent cellular senescence pathway both in vitro and in vivo, which can be fully rescued by combined loss of Trp53. Furthermore, we detected evidence of cellular senescence in specimens from early-stage human prostate cancer. Our results demonstrate the relevance of cellular senescence in restricting tumorigenesis in vivo and support a model for cooperative tumour suppression in which p53 is an essential failsafe protein of Pten-deficient tumours.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16079851      PMCID: PMC1939938          DOI: 10.1038/nature03918

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  30 in total

Review 1.  Molecular genetics of prostate cancer.

Authors:  C Abate-Shen; M M Shen
Journal:  Genes Dev       Date:  2000-10-01       Impact factor: 11.361

2.  Loss of a small region around the PTEN locus is a major chromosome 10 alteration in prostate cancer xenografts and cell lines.

Authors:  Karin G Hermans; Dirk C van Alewijk; Joris A Veltman; Wytske van Weerden; Ad Geurts van Kessel; Jan Trapman
Journal:  Genes Chromosomes Cancer       Date:  2004-03       Impact factor: 5.006

3.  Leveling of prostate cancer mortality in Western Europe.

Authors:  Fabio Levi; Franca Lucchini; Eva Negri; Peter Boyle; Carlo La Vecchia
Journal:  Prostate       Date:  2004-06-15       Impact factor: 4.104

4.  PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms.

Authors:  Daniel J Freeman; Andrew G Li; Gang Wei; Heng-Hong Li; Nathalie Kertesz; Ralf Lesche; Andrew D Whale; Hilda Martinez-Diaz; Nora Rozengurt; Robert D Cardiff; Xuan Liu; Hong Wu
Journal:  Cancer Cell       Date:  2003-02       Impact factor: 31.743

Review 5.  Cellular senescence as a tumor-suppressor mechanism.

Authors:  J Campisi
Journal:  Trends Cell Biol       Date:  2001-11       Impact factor: 20.808

6.  A biomarker that identifies senescent human cells in culture and in aging skin in vivo.

Authors:  G P Dimri; X Lee; G Basile; M Acosta; G Scott; C Roskelley; E E Medrano; M Linskens; I Rubelj; O Pereira-Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-26       Impact factor: 11.205

7.  A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus.

Authors:  L D Mayo; D B Donner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

8.  Regulation of PTEN transcription by p53.

Authors:  V Stambolic; D MacPherson; D Sas; Y Lin; B Snow; Y Jang; S Benchimol; T W Mak
Journal:  Mol Cell       Date:  2001-08       Impact factor: 17.970

9.  Cancer mortality surveillance--United States, 1990-2000.

Authors:  Sherri L Stewart; Jessica B King; Trevor D Thompson; Carol Friedman; Phyllis A Wingo
Journal:  MMWR Surveill Summ       Date:  2004-06-04

10.  Pten dose dictates cancer progression in the prostate.

Authors:  Lloyd C Trotman; Masaru Niki; Zohar A Dotan; Jason A Koutcher; Antonio Di Cristofano; Andrew Xiao; Alan S Khoo; Pradip Roy-Burman; Norman M Greenberg; Terry Van Dyke; Carlos Cordon-Cardo; Pier Paolo Pandolfi
Journal:  PLoS Biol       Date:  2003-10-27       Impact factor: 8.029

View more
  878 in total

1.  PRAK suppresses oncogenic ras-induced hematopoietic cancer development by antagonizing the JNK pathway.

Authors:  Naoto Yoshizuka; Maoyi Lai; Rong Liao; Ryan Cook; Changchun Xiao; Jiahuai Han; Peiqing Sun
Journal:  Mol Cancer Res       Date:  2012-06-04       Impact factor: 5.852

2.  Deregulation of oncogene-induced senescence and p53 translational control in X-linked dyskeratosis congenita.

Authors:  Cristian Bellodi; Noam Kopmar; Davide Ruggero
Journal:  EMBO J       Date:  2010-05-07       Impact factor: 11.598

Review 3.  Senescent cells: an emerging target for diseases of ageing.

Authors:  Bennett G Childs; Martina Gluscevic; Darren J Baker; Remi-Martin Laberge; Dan Marquess; Jamie Dananberg; Jan M van Deursen
Journal:  Nat Rev Drug Discov       Date:  2017-07-21       Impact factor: 84.694

4.  Interleukin-17 promotes metastasis in an immunocompetent orthotopic mouse model of prostate cancer.

Authors:  David Cunningham; Qiuyang Zhang; Sen Liu; Keshab R Parajuli; Qiang Nie; Lin Ma; Allen Zhang; Zhenbang Chen; Zongbing You
Journal:  Am J Clin Exp Urol       Date:  2018-06-15

5.  Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors.

Authors:  Mona L Gauthier; Hal K Berman; Caroline Miller; Krystyna Kozakeiwicz; Karen Chew; Dan Moore; Joseph Rabban; Yunn Yi Chen; Karla Kerlikowske; Thea D Tlsty
Journal:  Cancer Cell       Date:  2007-11       Impact factor: 31.743

6.  Akt activation synergizes with Trp53 loss in oral epithelium to produce a novel mouse model for head and neck squamous cell carcinoma.

Authors:  Marta Moral; Carmen Segrelles; M Fernanda Lara; Ana Belén Martínez-Cruz; Corina Lorz; Mirentxu Santos; Ramón García-Escudero; Jerry Lu; Kaoru Kiguchi; Agueda Buitrago; Clotilde Costa; Cristina Saiz; Jose L Rodriguez-Peralto; Francisco J Martinez-Tello; Maria Rodriguez-Pinilla; Montserrat Sanchez-Cespedes; Marina Garín; Teresa Grande; Ana Bravo; John DiGiovanni; Jesús M Paramio
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

7.  Differential requirement of mTOR in postmitotic tissues and tumorigenesis.

Authors:  Caterina Nardella; Arkaitz Carracedo; Andrea Alimonti; Robin M Hobbs; John G Clohessy; Zhenbang Chen; Ainara Egia; Alessandro Fornari; Michelangelo Fiorentino; Massimo Loda; Sara C Kozma; George Thomas; Carlos Cordon-Cardo; Pier Paolo Pandolfi
Journal:  Sci Signal       Date:  2009-01-27       Impact factor: 8.192

Review 8.  Cell cycle, CDKs and cancer: a changing paradigm.

Authors:  Marcos Malumbres; Mariano Barbacid
Journal:  Nat Rev Cancer       Date:  2009-03       Impact factor: 60.716

9.  Crosstalk between nuclear MET and SOX9/β-catenin correlates with castration-resistant prostate cancer.

Authors:  Yingqiu Xie; Wenfu Lu; Shenji Liu; Qing Yang; Brett S Carver; Estelle Li; Yuzhuo Wang; Ladan Fazli; Martin Gleave; Zhenbang Chen
Journal:  Mol Endocrinol       Date:  2014-08-06

10.  Targeting cancer metabolism by simultaneously disrupting parallel nutrient access pathways.

Authors:  Seong M Kim; Saurabh G Roy; Bin Chen; Tiffany M Nguyen; Ryan J McMonigle; Alison N McCracken; Yanling Zhang; Satoshi Kofuji; Jue Hou; Elizabeth Selwan; Brendan T Finicle; Tricia T Nguyen; Archna Ravi; Manuel U Ramirez; Tim Wiher; Garret G Guenther; Mari Kono; Atsuo T Sasaki; Lois S Weisman; Eric O Potma; Bruce J Tromberg; Robert A Edwards; Stephen Hanessian; Aimee L Edinger
Journal:  J Clin Invest       Date:  2016-09-26       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.